Skip to content

Study · Animal study (in vivo) · mouse · 2019

3 results

Metabolomic profile of diet-induced obesity mice in response to humanin and small humanin-like peptide 2 treatment.

Mehta HH, Xiao J, Ramirez R, Miller B, Kim SJ, Cohen P, Yen K

Metabolomics : Official journal of the Metabolomic Society6 Jun 2019Cited by 42 (Europe PMC)

PMID31172328 (opens in a new tab)PMCIDPMC6554247 (opens in a new tab)DOI10.1007/s11306-019-1549-7 (opens in a new tab)PepBankPUB-31172328
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

IntroductionThe mitochondrial-derived peptides (MDPs) are a novel group of natural occurring peptides that have important signaling functions and biological activity. Both humanin and small-humanin-like peptide 2 (SHLP2) have been reported to act as insulin sensitizers and modulate metabolism.ObjectivesBy using a metabolomic approach, this study explores how the plasma metabolite profile is regulated in response to humanin and SHLP2 treatment in a diet-induced obesity (DIO) mouse model. The results also shed light on the potential mechanism underlying MDPs' insulin sensitization effects.MethodsPlasma samples were obtained from DIO mice subjected to vehicle (water) treatment, or peptide treatment with either humanin analog S14G (HNG) or SHLP2 (n = 6 per group). Vehicle or peptides were given as intraperitoneal (IP) injections twice a day at dose of 2.5 mg/kg/injection for 3 days. Metabolites in plasma samples were comprehensively identified and quantified using UPLC-MS/MS.ResultsHNG and SHLP2 administration significantly altered the concentrations of amino acid and lipid metabolites in plasma. Among all the metabolic pathways, the glutathione and sphingolipid metabolism responded most strongly to the peptide treatment.ConclusionsThe present study indicates that humanin and SHLP2 can lower several markers associated with age-related metabolic disorders. With the previous understanding of the effects of humanin and SHLP2 on cardiovascular function, insulin sensitization, and anti-inflammation, this metabolomic discovery provides a more comprehensive molecular explanation of the mechanism of action for humanin and SHLP2 treatment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In diet-induced obese mice, HNG significantly altered plasma concentrations of amino acid metabolites versus vehicle.

    In plain wordsIn obese mice, HNG changed the levels of amino acid metabolites in blood compared with vehicle.

    Peptide
    Humanin
    Outcome
    MixedPlasma amino acid metabolite concentrations
    Study

    mousen = 6

    Diet-induced obesity (DIO) mice
    Comparator
    Vehicle (water)
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    2.5 mg/kg/injection twice a day · intraperitoneal injection · 3 daysAs given in this study (mouse).

    Source sentences

    Summary
    HNG and SHLP2 administration significantly altered the concentrations of amino acid and lipid metabolites in plasma.
    2 context sentences
    Summary · context
    Plasma samples were obtained from DIO mice subjected to vehicle (water) treatment, or peptide treatment with either humanin analog S14G (HNG) or SHLP2 (n = 6 per group).
    Summary · context
    Vehicle or peptides were given as intraperitoneal (IP) injections twice a day at dose of 2.5 mg/kg/injection for 3 days.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diet-induced obese mice, HNG significantly altered plasma concentrations of lipid metabolites versus vehicle.

    In plain wordsIn obese mice, HNG changed the levels of lipid metabolites in blood compared with vehicle.

    Peptide
    Humanin
    Outcome
    MixedPlasma lipid metabolite concentrations
    Study

    mousen = 6

    Diet-induced obesity (DIO) mice
    Comparator
    Vehicle (water)
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    2.5 mg/kg/injection twice a day · intraperitoneal injection · 3 daysAs given in this study (mouse).

    Source sentences

    Summary
    HNG and SHLP2 administration significantly altered the concentrations of amino acid and lipid metabolites in plasma.
    2 context sentences
    Summary · context
    Plasma samples were obtained from DIO mice subjected to vehicle (water) treatment, or peptide treatment with either humanin analog S14G (HNG) or SHLP2 (n = 6 per group).
    Summary · context
    Vehicle or peptides were given as intraperitoneal (IP) injections twice a day at dose of 2.5 mg/kg/injection for 3 days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diet-induced obese mice, glutathione and sphingolipid metabolism responded most strongly to HNG treatment among all metabolic pathways.

    In plain wordsIn obese mice, glutathione and sphingolipid metabolism changed the most after HNG treatment.

    Peptide
    Humanin
    Outcome
    MixedGlutathione and sphingolipid metabolism pathways
    Study

    mousen = 6

    Diet-induced obesity (DIO) mice
    Comparator
    Vehicle (water)
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    2.5 mg/kg/injection twice a day · intraperitoneal injection · 3 daysAs given in this study (mouse).

    Source sentences

    Summary
    Among all the metabolic pathways, the glutathione and sphingolipid metabolism responded most strongly to the peptide treatment.
    2 context sentences
    Summary · context
    Plasma samples were obtained from DIO mice subjected to vehicle (water) treatment, or peptide treatment with either humanin analog S14G (HNG) or SHLP2 (n = 6 per group).
    Summary · context
    Vehicle or peptides were given as intraperitoneal (IP) injections twice a day at dose of 2.5 mg/kg/injection for 3 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.